Literature DB >> 29429898

Structural Basis for Inhibitor-Induced Hydrogen Peroxide Production by Kynurenine 3-Monooxygenase.

Hyun Tae Kim1, Byeong Kwan Na2, Jiwoung Chung2, Sulhee Kim3, Sool Ki Kwon2, Hyunju Cha2, Jonghyeon Son3, Joong Myung Cho4, Kwang Yeon Hwang5.   

Abstract

Kynurenine 3-monooxygenase (KMO) inhibitors have been developed for the treatment of neurodegenerative disorders. The mechanisms of flavin reduction and hydrogen peroxide production by KMO inhibitors are unknown. Herein, we report the structure of human KMO and crystal structures of Saccharomyces cerevisiae (sc) and Pseudomonas fluorescens (pf) KMO with Ro 61-8048. Proton transfer in the hydrogen bond network triggers flavin reduction in p-hydroxybenzoate hydroxylase, but the mechanism triggering flavin reduction in KMO is different. Conformational changes via π-π interactions between the loop above the flavin and substrate or non-substrate effectors lead to disorder of the C-terminal α helix in scKMO and shifts of domain III in pfKMO, stimulating flavin reduction. Interestingly, Ro 61-8048 has two different binding modes. It acts as a competitive inhibitor in scKMO and as a non-substrate effector in pfKMO. These findings provide understanding of the catalytic cycle of KMO and insight for structure-based drug design of KMO inhibitors.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  KMO inhibitor; drug design; flavin reduction; hydrogen peroxide; kynurenine 3-monooxygenase

Mesh:

Substances:

Year:  2018        PMID: 29429898     DOI: 10.1016/j.chembiol.2018.01.008

Source DB:  PubMed          Journal:  Cell Chem Biol        ISSN: 2451-9448            Impact factor:   8.116


  8 in total

Review 1.  Advantages of brain penetrating inhibitors of kynurenine-3-monooxygenase for treatment of neurodegenerative diseases.

Authors:  Shaowei Zhang; Mary E W Collier; Derren J Heyes; Flaviano Giorgini; Nigel S Scrutton
Journal:  Arch Biochem Biophys       Date:  2020-12-01       Impact factor: 4.013

2.  Full-length in meso structure and mechanism of rat kynurenine 3-monooxygenase inhibition.

Authors:  Shinya Mimasu; Hiroaki Yamagishi; Satoshi Kubo; Mie Kiyohara; Toshihiro Matsuda; Toshiko Yahata; Heather A Thomson; Christopher D Hupp; Julie Liu; Takao Okuda; Kenichi Kakefuda
Journal:  Commun Biol       Date:  2021-02-04

Review 3.  The Kynurenine Pathway and Kynurenine 3-Monooxygenase Inhibitors.

Authors:  Tamera D Hughes; Osman F Güner; Emma Carine Iradukunda; Robert S Phillips; J Phillip Bowen
Journal:  Molecules       Date:  2022-01-02       Impact factor: 4.411

Review 4.  Kynurenic acid in neurodegenerative disorders-unique neuroprotection or double-edged sword?

Authors:  Aleksandra Ostapiuk; Ewa M Urbanska
Journal:  CNS Neurosci Ther       Date:  2021-12-03       Impact factor: 5.243

5.  Identification of enzymes that have helminth-specific active sites and are required for Rhodoquinone-dependent metabolism as targets for new anthelmintics.

Authors:  Margot J Lautens; June H Tan; Xènia Serrat; Samantha Del Borrello; Michael R Schertzberg; Andrew G Fraser
Journal:  PLoS Negl Trop Dis       Date:  2021-11-29

6.  Kynurenine-3-monooxygenase (KMO) broadly inhibits viral infections via triggering NMDAR/Ca2+ influx and CaMKII/ IRF3-mediated IFN-β production.

Authors:  Jin Zhao; Jiaoshan Chen; Congcong Wang; Yajie Liu; Minchao Li; Yanjun Li; Ruiting Li; Zirong Han; Junjian Wang; Ling Chen; Yuelong Shu; Genhong Cheng; Caijun Sun
Journal:  PLoS Pathog       Date:  2022-03-02       Impact factor: 6.823

7.  Pharmacophore-Based Virtual Screening of Novel Competitive Inhibitors of the Neurodegenerative Disease Target Kynurenine-3-Monooxygenase.

Authors:  Lizaveta Gotina; Seon Hee Seo; Chae Won Kim; Sang Min Lim; Ae Nim Pae
Journal:  Molecules       Date:  2021-05-31       Impact factor: 4.411

Review 8.  Kynurenine-3-monooxygenase: A new direction for the treatment in different diseases.

Authors:  Yifei Lu; Mingmei Shao; Tao Wu
Journal:  Food Sci Nutr       Date:  2020-01-20       Impact factor: 2.863

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.